Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INS1GHT
2025-522528-29-00Phase 2Authorised
- Sponsor
- Gentofte Hospital
- Start
- Sep 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Colchicine with Placebo (2 arms). Primary endpoint: Change in M-value after four weeks of placebo/colchicine. Planned start Sep 2025; status: authorised.
02
Drugs
colchicine
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2025-522528-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522528-29-00.